<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631004</url>
  </required_header>
  <id_info>
    <org_study_id>1287/18</org_study_id>
    <nct_id>NCT03631004</nct_id>
  </id_info>
  <brief_title>Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients</brief_title>
  <official_title>Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Olanzapine has been used as prophylactic antiemetic for chemotherapy induced nausea and&#xD;
      vomiting.&#xD;
&#xD;
      The project aims to evaluate the efficacy of olanzapine in combination with ondansetron and&#xD;
      dexamethasone in patients at high risk of postoperative nausea and vomiting, with previous&#xD;
      history of nausea and vomiting induced by prior chemotherapy, submitted to medium and large&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blinded randomized clinical trial. Fifty patients will be selected for each group.&#xD;
      Group A will receive 10mg olanzapine in the preoperative and group B will receive placebo in&#xD;
      the preoperative period. Both groups will receive intravenous general anesthesia combined&#xD;
      with epidural. All patients will receive epidural PCA.&#xD;
&#xD;
      The primary outcome of this study is the incidence of post-operative nausea and vomiting. The&#xD;
      power of analysis was based on the following parameters: type error I (α = 0.05), error II (β&#xD;
      = 0.8), 95% confidence interval and hypothesis test two-tailed. Thus, 42 patients are&#xD;
      indicated per group to obtain reduction of the incidence of nausea and / or vomiting of the&#xD;
      population risk from 60% to 30%. The population will be composed of 100 patients because it&#xD;
      is assumed that percentage of loss of 10% per group.&#xD;
&#xD;
      The statistical analysis will be performed in program R version 3.5.1. The results obtained&#xD;
      will be presented as mean + standard deviation for continuous data or absolute frequency for&#xD;
      described data.&#xD;
&#xD;
      For quantitative variables, the Student's t-test will be used for with normal distribution or&#xD;
      Mann-Whitney for non-distributed data normal.&#xD;
&#xD;
      For qualitative variables, the chi-square test will be used or Fisher's exact test.&#xD;
      Significant difference is defined as p, 0.05.&#xD;
&#xD;
      Data will be collected and managed using REDCap data capture tools&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">February 10, 2021</completion_date>
  <primary_completion_date type="Actual">February 10, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative nausea</measure>
    <time_frame>48 hours</time_frame>
    <description>any episode of nausea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative vomiting</measure>
    <time_frame>48 hours</time_frame>
    <description>any episode of vomiting</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative retching</measure>
    <time_frame>48 hours</time_frame>
    <description>any episode of retching</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>48 hours</time_frame>
    <description>side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Postoperative Nausea</condition>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>olanzapine tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PATIENT WILL TAKE OLANZAPINE 10 MG, 1 hour BEFORE SURGERY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Starch tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PATIENT WILL TAKE PLACEBO 1 hour BEFORE SURGERY</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>olanzapine 10 mg is given before surgery</description>
    <arm_group_label>Starch tablets</arm_group_label>
    <arm_group_label>olanzapine tablets</arm_group_label>
    <other_name>Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients submitted to medium and large surgeries in the thoracic or abdominal region&#xD;
             (mastectomies, breast plastic, hysterectomies, annexectomies, gynecological pelvic&#xD;
             surgeries, colectomies, rettosigmoidectomies) under general anesthesia&#xD;
&#xD;
          -  Patients aged between 18 and 60 years&#xD;
&#xD;
          -  Patients considered to be at high risk for PONV according to the Apfel scale (Apfel 3&#xD;
             or 4)&#xD;
&#xD;
          -  Patients with a history of chemotherapy-induced nausea and vomiting.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pregnancy or Lactation&#xD;
&#xD;
          -  Current use of typical anti-psychotic medications or atypical&#xD;
&#xD;
          -  History of allergy to olanzapine&#xD;
&#xD;
          -  Myocardial infarction or unstable angina in the 6 months prior to the day of surgery&#xD;
             planning&#xD;
&#xD;
          -  History of severe ventricular arrhythmia (eg, VT or VF)&#xD;
&#xD;
          -  Heart Failure Class II or greater second NYHA&#xD;
&#xD;
          -  Postural hypotension or vasovagal syncope in the 6 months prior to the day of surgery&#xD;
             planning&#xD;
&#xD;
          -  Narrow angle glaucoma&#xD;
&#xD;
          -  Parkinson's disease&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Inability to swallow medicines&#xD;
&#xD;
          -  QT interval history greater than 450ms or torsades de pointes&#xD;
&#xD;
          -  Patient does not want to participate in the study&#xD;
&#xD;
          -  Videolaparoscopy surgery&#xD;
&#xD;
          -  Contraindication for neuraxial block&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Chammas</last_name>
    <role>Study Director</role>
    <affiliation>Instituto do Cancer do Estado de São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute of the State of Sao Paulo - ICESP</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>01403010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 11, 2018</study_first_submitted>
  <study_first_submitted_qc>August 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nausea and vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

